Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-Parkinson's disease drugs and pharmacogenetic considerations

9 Apr 2013

Abstract excerpt

INTRODUCTION: The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers. These biomarkers are then used as surrogate endpoints. This review analyzes potential genetic biomarkers which can be used to improve anti-Parkinson's disease therapy. AREAS COVERED: The authors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23565891
DOI: 10.1517/17425255.2013.789018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-Parkinson's disease drugs and pharmacogenetic considerationsPMID 23565891Read ↗

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Semantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic StudiesSemantic proximity Read ↗

A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?Semantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.Semantic proximity Read ↗

Pharmacogenetics of Clinical Response to RisperioneSemantic proximity Read ↗

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Semantic proximity Read ↗

Parkinson’s Disease: Biomarkers, Treatment, and Risk FactorsSemantic proximity Read ↗

Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.Semantic proximity Read ↗

The role of pharmacogenomics in the personalization of Parkinson's disease treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.